Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m
Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m
Key Insights
主要见解
- Heilongjiang ZBD Pharmaceutical's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public
- Heilongjiang Chuangda Group Co., Ltd. owns 50% of the company
- Ownership research, combined with past performance data can help provide a good understanding of opportunities in a stock
- 珍宝岛制药的重要的股权投资公司持股表明,其关键决策受到来自大众股东的影响。
- 黑龙江创达集团有限公司拥有该公司50%的股份。
- 所有权研究结合过去的表现数据可以帮助更好地理解股票的机会。
If you want to know who really controls Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private equity firms with 55% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
如果你想知道谁真正控制着黑龙江珍宝岛制药股份有限公司(SHSE:603567),那么你就得看一下它的股权登记簿构成。掌握市场最大份额的是持有55%股权的股权投资公司。换句话说,该组织从其投资中获得或损失的最多。
As a result, private equity firms as a group endured the highest losses last week after market cap fell by CN¥517m.
因此,在市值下降了51700万的情况下,作为一个整体,股权投资公司遭受了最大的损失。
Let's take a closer look to see what the different types of shareholders can tell us about Heilongjiang ZBD Pharmaceutical.
让我们更仔细地看看不同类型的股东对于黑龙江珍宝岛制药能告诉我们些什么。
What Does The Institutional Ownership Tell Us About Heilongjiang ZBD Pharmaceutical?
机构所有权对珍宝岛制药有何影响?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
We can see that Heilongjiang ZBD Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Heilongjiang ZBD Pharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看到,珍宝岛制药确实拥有机构投资者,并且他们持有公司的大部分股份。这可能表明该公司在投资社区中具有一定的信誉度。然而,最好还是谨慎依赖机构投资者带来的所谓认可。他们有时候也会犯错。如果两家大型机构投资者同时试图抛售某一只股票,股价暴跌也是很常见的情况。因此,值得检查珍宝岛制药的过去收益轨迹(见下文) 。当然,也要记住还有其他因素需要考虑。
We note that hedge funds don't have a meaningful investment in Heilongjiang ZBD Pharmaceutical. Heilongjiang Chuangda Group Co., Ltd. is currently the company's largest shareholder with 50% of shares outstanding. This implies that they have majority interest control of the future of the company. For context, the second largest shareholder holds about 5.9% of the shares outstanding, followed by an ownership of 5.0% by the third-largest shareholder.
我们注意到,对于珍宝岛制药,对冲基金在其中没有意义性的投资。黑龙江创达集团有限公司是目前该公司持股最多的股东,拥有50%的流通股份。这意味着他们对该公司的未来有绝对的控制权。作为背景,第二大股东持有流通股份的约5.9%,第三大股东持有5.0%的股权。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
尽管研究一家公司的机构所有权可以为您的研究增添价值,但研究分析师建议以深入了解股票的预期表现也是一个好的做法。我们的信息表明,该股票没有任何分析师的覆盖,因此可能为人所知甚少。
Insider Ownership Of Heilongjiang ZBD Pharmaceutical
珍宝岛制药的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
内部人员的定义在不同国家之间可能略有不同,但董事会成员始终计数。公司管理层回答董事会,在此应代表股东利益。值得注意的是,有时高级管理人员也在董事会上。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。
Our most recent data indicates that insiders own less than 1% of Heilongjiang ZBD Pharmaceutical Co., Ltd.. But they may have an indirect interest through a corporate structure that we haven't picked up on. It's a big company, so even a small proportional interest can create alignment between the board and shareholders. In this case insiders own CN¥6.4m worth of shares. It is always good to see at least some insider ownership, but it might be worth checking if those insiders have been selling.
我们最新的数据表明,珍宝岛制药股份有限公司的内部人员持股比例不到1%。但他们可能通过我们没有注意到的公司架构间接持有利益。它是一家大型公司,因此即使是小比例的持股也足以创造董事会和股东之间的一致性。在这种情况下,内部人员拥有价值640万人民币的股票。看到至少拥有一些内部所有权总是好的,但我们可能需要检查那些内部人员是否一直在卖股票。
General Public Ownership
一般大众所有权
The general public-- including retail investors -- own 31% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公众 - 包括散户投资者 - 持有公司31%的股份,因此不能轻易被忽视。虽然此种持股规模可能不足以在他们的利益中左右决策,但他们仍然可以对公司政策产生集体影响。
Private Equity Ownership
股权投资公司持有8.8%的股份,有能力参与塑造以价值创造为重点的公司策略。一些投资者可能会因此而受到鼓舞,因为股权投资公司有时可以鼓励市场看到公司的价值,从而采取有益的策略。另外,那些持有者可能在将其上市后退出投资。
With an ownership of 55%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
持有55%的股权投资公司在塑造以价值创造为重点的公司战略方面处于一个位置。有时我们会看到私募股权投资长期持有,但总的来说,他们的投资时间较短,并且如其名称所示,不会在公共公司中投资太多。一段时间后,他们可能会寻求出售并重新部署资本。
Private Company Ownership
私有公司的所有权
Our data indicates that Private Companies hold 6.2%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我们的数据表明,私人公司持有该公司股份的6.2%。私人公司可能是相关方。有时,内部人员通过持有私人公司的股份来参与公共公司。虽然很难得出任何广泛的结论,但值得注意的是作为进一步研究的领域。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Heilongjiang ZBD Pharmaceutical (at least 1 which shouldn't be ignored) , and understanding them should be part of your investment process.
尽管考虑到拥有一家公司的不同集团值得深思,但还有其他更重要的因素需要考虑。例如,不断存在的投资风险。我们已经确定了2个警示信号,其中至少1个不应被忽视,了解它们应该是您的投资过程的一部分。
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
如果您更喜欢核对具有潜在优越财务状况的其他公司,则不要错过此免费的备有强大财务数据支持的有趣公司列表。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。